These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 10801168)
1. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168 [TBL] [Abstract][Full Text] [Related]
2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Pastores GM; Barnett NL; Kolodny EH Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246 [TBL] [Abstract][Full Text] [Related]
3. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381 [TBL] [Abstract][Full Text] [Related]
5. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease. Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Gaucher's disease with OGT 918. Kranda M Lancet; 2000 Aug; 356(9230):677. PubMed ID: 10968455 [No Abstract] [Full Text] [Related]
7. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Moyses C Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929 [TBL] [Abstract][Full Text] [Related]
8. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Heitner R; Elstein D; Aerts J; Weely Sv; Zimran A Blood Cells Mol Dis; 2002; 28(2):127-33. PubMed ID: 12064906 [TBL] [Abstract][Full Text] [Related]
13. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy. Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070 [TBL] [Abstract][Full Text] [Related]
14. Gaucher disease and the clinical experience with substrate reduction therapy. Zimran A; Elstein D Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930 [TBL] [Abstract][Full Text] [Related]
15. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Pastores GM; Elstein D; Hrebícek M; Zimran A Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546 [TBL] [Abstract][Full Text] [Related]
16. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report. Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156 [TBL] [Abstract][Full Text] [Related]
17. A less costly regimen of alglucerase to treat Gaucher's disease. Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900 [TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Schiffmann R; Fitzgibbon EJ; Harris C; DeVile C; Davies EH; Abel L; van Schaik IN; Benko W; Timmons M; Ries M; Vellodi A Ann Neurol; 2008 Nov; 64(5):514-22. PubMed ID: 19067373 [TBL] [Abstract][Full Text] [Related]
19. Gaucher's disease in Lithuania: its diagnosis and treatment. Kleinotienė G; Tylki-Szymanska A; Czartoryska B Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991 [TBL] [Abstract][Full Text] [Related]
20. Alglucerase. A review of its therapeutic use in Gaucher's disease. Whittington R; Goa KL Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]